
Lupin introduces a generic medication to the US market
Lupin has launched Sevelamer Hydrochloride tablets (800 mg) in the US market to treat hyperphosphatemia in patients with chronic kidney disease. After receiving approval from the US Food and Drug Administration, the company launched the product (USFDA).